.Attribute Medication, Posted online: thirteen September 2024 doi:10.1038/ s41591-024-03261-7In the non-randomized period 3b/4 DESTINY-Breast12 research study, trastuzumab deruxtecan (T-DXd) treatment of patients with HER2+ enhanced bosom cancer cells and energetic or dependable brain metastases presented steady intracranial activity and also systemic effectiveness of T-DXd.